Howard J. Glenn

680 total citations
37 papers, 505 citations indexed

About

Howard J. Glenn is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Howard J. Glenn has authored 37 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Howard J. Glenn's work include Radiopharmaceutical Chemistry and Applications (19 papers), Medical Imaging Techniques and Applications (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Howard J. Glenn is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (19 papers), Medical Imaging Techniques and Applications (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Howard J. Glenn collaborates with scholars based in United States, United Kingdom and India. Howard J. Glenn's co-authors include Thomas P. Haynie, Michael G. Rosenblum, Evan M. Hersh, Dennis J. Carlo, James L. Murray, Leela P. Kasi, Gabriel Lopez‐Berestein, Giora M. Mavligit, R T Mehta and L. Lamki and has published in prestigious journals such as Journal of the American Chemical Society, The Journal of Clinical Endocrinology & Metabolism and The Journal of Urology.

In The Last Decade

Howard J. Glenn

37 papers receiving 472 citations

Peers

Howard J. Glenn
Sudhir Shah United States
K Hasumi Japan
Baldwin H. Tom United States
Marc A. Longino United States
Daniel G. Mackensen United States
Forrest E. Gaul United States
Glen Teshima United States
RG Melton United Kingdom
Christine Fazenbaker United States
Sudhir Shah United States
Howard J. Glenn
Citations per year, relative to Howard J. Glenn Howard J. Glenn (= 1×) peers Sudhir Shah

Countries citing papers authored by Howard J. Glenn

Since Specialization
Citations

This map shows the geographic impact of Howard J. Glenn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard J. Glenn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard J. Glenn more than expected).

Fields of papers citing papers by Howard J. Glenn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard J. Glenn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard J. Glenn. The network helps show where Howard J. Glenn may publish in the future.

Co-authorship network of co-authors of Howard J. Glenn

This figure shows the co-authorship network connecting the top 25 collaborators of Howard J. Glenn. A scholar is included among the top collaborators of Howard J. Glenn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard J. Glenn. Howard J. Glenn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Murray, James L., Michael G. Rosenblum, L. Lamki, et al.. (1987). Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018.. PubMed. 28(1). 25–33. 48 indexed citations
2.
Murray, James L., Michael G. Rosenblum, L. Lamki, et al.. (1987). Radioimmunoimaging in malignant melanoma patients with the use of indium-111-labeled antimelanoma monoclonal antibody (ZME-018) to high-molecular-weight antigen.. PubMed. 3–9. 12 indexed citations
3.
Babaian, R. Joseph, James L. Murray, L. Lamki, et al.. (1987). Radioimmunological Imaging of Metastatic Prostatic Cancer with111Indium-Labeled Monoclonal Antibody Pay 276. The Journal of Urology. 137(3). 439–443. 34 indexed citations
4.
Murray, James L., Marc K. Rosenblum, L. Lamki, et al.. (1985). Imaging findings and pharmacokinetics of 111-indium ZME-018 monoclonal antibody (MoAb) in malignant melanoma. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 64(6). 385–390. 1 indexed citations
5.
Pérez-Soler, Román, Gabriel Lopez‐Berestein, Leela P. Kasi, et al.. (1985). Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease.. PubMed. 26(7). 743–9. 34 indexed citations
6.
Glenn, Howard J.. (1982). Biologic applications of radiotracers. CERN Document Server (European Organization for Nuclear Research). 16 indexed citations
7.
Hersh, Evan M., Jordan U. Gutterman, Thomas P. Haynie, et al.. (1981). Organ distributions and clearance studies of 99m technetium-labeled corynebacterium parvum in patients with leukemia. International Journal of Immunopharmacology. 3(2). 141–145. 1 indexed citations
8.
Hersh, Evan M., et al.. (1981). Use of mini-microaggregated albumin® to study reticuloendothelial system (RES) function in C. parvum-treated animals. International Journal of Immunopharmacology. 3(2). 147–152. 3 indexed citations
9.
Suzuki, Norio, et al.. (1977). Radiation damage to mouse testis cells from [99mTc] pertechnetate.. PubMed. 18(11). 1116–22. 19 indexed citations
10.
Haynie, Thomas P., et al.. (1976). Experimental models for evaluation of radioactive tumor-localizing agents. Seminars in Nuclear Medicine. 6(4). 347–369. 3 indexed citations
11.
Glenn, Howard J., et al.. (1976). Leukocyte labeling with technetium-99m. International Journal of Nuclear Medicine and Biology. 3(1). 9–15. 5 indexed citations
12.
Haynie, Thomas P., et al.. (1975). Brain tumor-scanning agents compared in an animal model.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 16(3). 200–7. 9 indexed citations
13.
Haynie, Thomas P., et al.. (1975). Kinetics of 111In-bleomycin and 111 In-chlorides in mice.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 16(8). 738–43. 11 indexed citations
14.
Glenn, Howard J., et al.. (1974). A simplified procedure for the labelling of thyroid hormones. The International Journal of Applied Radiation and Isotopes. 25(9). 421–422. 3 indexed citations
15.
Glenn, Howard J., et al.. (1973). Kinetics of 67 Ga compounds in brain sarcomas and kidneys of mice.. PubMed. 14(3). 164–71. 10 indexed citations
16.
Glenn, Howard J., et al.. (1972). Renal clearance and brain tumor localization in mice of 99 m Tc compounds of (Sn), DTPA, (iron-ascorbic acid) DTPA, and iron-ascorbic acid.. PubMed. 13(11). 834–42. 7 indexed citations
17.
Samaan, Naguib A., et al.. (1972). Thyrotropin-Releasing Hormone (TRH) Studies in Patients with Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 35(3). 438–443. 6 indexed citations
18.
Zaugg, Harold E., et al.. (1958). Tertiary Carbinols of the Piperazine Series. I. Journal of the American Chemical Society. 80(11). 2763–2768. 9 indexed citations
19.
Zaugg, Harold E., et al.. (1957). Reactions of α,α-Diphenyl-β-propiolactone with Amines and Thiols. Journal of the American Chemical Society. 79(14). 3912–3915. 9 indexed citations
20.
Glenn, Howard J., et al.. (1954). Analgesics Derived from Tetrahydroacenaphthones1. Journal of the American Chemical Society. 76(14). 3640–3642. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026